anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This group will intake the recommended daily amount of the food supplement VSL#3 (two sachets of the supplement in powder form) every day for twelve weeks. The two sachets will either be taken together or one in the morning and one in the evening.
Placebo to Sitagliptin, once daily, orally for 12 weeks. Participants randomized to the placebo treatment group during the base study were reallocated to treatment with metformin 850 mg twice daily (b.i.d., initiated with 850 mg q.d. for 4 weeks then force titrated to 850 mg b.i.d.) during either the first or initiation of the second extensions study periods.
The invention discloses a production process for preparing a skin-nonstick ache plaster. The medical plaster passing the inspection of the National Bureau of Drug Surveillance is adopted for preparing the invention, an infrared and anion fabric is selected and the infrared natural rubber latex invented by Lian Changjing in Tianjin municipality is also adopted. A circular magnetic slice is adhered on the rubber latex. The materials are made into a bag with edge adhesive material, and then the medication plater is adhered into the bag. The skin-nonstick ache plaster is adhered on the focus of the patient. The invention is durable in a long term and the paste with medical total value can develop 2-3 times more treatment period than the original plaster. Together with the infrared anion physical therapy allowing magnetic therapy, the invention is an ideal plaster for treating various joint aches, activating blood and dredging channels, eliminating swelling and relieving pain, expelling wind and dispelling cold and removing tumidness and anaesthesia.
The trial is designed to compare effectiveness between anthracycline and/or taxane as neoadjuvant chemotherapy for operable advanced breast cancer in different molecular typing. In this trial the investigators will randomly assign 200 primary breast cancer patients to receive six cycles of fluorourcil, epirubicin,and cyclophosphamide(FEC), or four cycles of epirubicin and cyclophosphamide (EC) followed by four cycles of docetaxel(T), or six cycles of docetaxel and cyclophosphamide (TC). Trasuzumab was recommended combining docetaxel to patients if HER-2 positive.The effectiveness of therapy will be estimated after every two cycles of neoadjuvant chemotherapy. Surgery will be performed after completing designated full cycles of neoadjuvant chemotherapy. The primary endpoint is to assess pathologic complete response (pCR, ypT0/is ypN0) rate in different regiments. The secondary endpoint is to assess the relationship between pCR rate with molecular typing in different regiments, so that the investigators could optimize neoadjuvant chemotherapy regiment according to molecular typing.
PURPOSE:To observe an entire picture and to diagnose an ROI in detail by processing only the area where the ROI is set with the window conversion conditions different from those of the periphery. CONSTITUTION:A window comparator 6 applies the window conversion processing to an original picture stored in an image memory 5 under the optimum window conversion conditions and displayed the processed picture on a display 11. When an ROI is set on said picture by a pointing device 14, this ROI undergoes the window conversion processing based on the window conversion conditions set separately. Then the picture is displayed. Thus two types of pictures (the ROI picture and its peripheral picture) of different window conversion conditions are displayed on the same screen. Thus it is possible to observe totally and at one time the desired areas.
PURPOSE: To obtain a polyether polymer excellent in hue and useful as e.g. a starting material for cosmetics by bringing a polyether polymer derived from a polyepihalohydrin into contact with a specified compound. CONSTITUTION: Nitrogenous groups are introduced into a polyepihalohydrin comprising repeating units of formula I (wherein V is a halogen; and m has an average of 10-1,500) to obtain a polyether polymer comprising repeating units represented by formula II [wherein Y is a group of formula III or IV (wherein R<1> and R<2> are each a 1-20C (hydroxy) alkyl or alkenyl; and Z is a 1-20C (hydroxy) alkylene)] and bringing this polymer into contact with a boron hydride compound. The decolorization reaction of the polymer with the boron hydride compound is carried out in a solution. The solvents used are desriably alcohols and water, particularly desirably water. The boron hydride compound is particularly desirably sodium boron hydride.
OBJECTIVE: To explore the potential of intratumoral metabolism and its heterogeneous parameters, as measured by preoperative fluorine-18-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) imaging, to predict mediastinal occult lymph node metastasis in cN0 lung invasive adenocarcinoma.
SUBJECTS AND METHODS: Seventy five patients were consecutively enrolled from January 2018 to December 2022. All patients underwent 18F-FDG PET/CT scans within two weeks before surgery, and had mediastinal lymph node metastasis confirmed by pathologic diagnosis after surgery. Metabolic parameters including the maximum standardized uptake value (SUVmax), mean SUV (SUVmean), maximum average SUV (SUVpeak), tumor metabolic volume (MTV), and metabolic heterogeneity (HF) were measured. The relationship between primary focal metabolism, its heterogeneity parameters, and occult mediastinal lymph node metastasis was analyzed using an independent-sample t-test, analysis of covariance, and Mann-Whitney U test. A multivariate logistic regression model was used to analyze independent risk factors for mediastinal lymph node metastasis, while the receiver operating characteristic (ROC) curve assessed the predictive value of metabolic heterogeneity parameters for mediastinal occult lymph node metastasis.
RESULTS: A total of 20 out of 75 patients (26.7%) were pathologically confirmed to have mediastinal lymph node metastasis. Analysis of covariance showed that the SUVmax, SUVmean, SUVpeak and MTV were significantly higher in patients with metastasis than in those without (all P<0.05). The metabolic heterogeneity parameters HF2 and HF3 were significantly higher in patients with mediastinal lymph node metastasis than in those without (P=0.013, 0.001), but not HF1. Multivariate Logistic regression analysis identified that tumor size, SUVmax, SUVpeak, lymph node SUVmax, and HF2 of the primary tumor as independent risk factors for mediastinal lymph node metastasis. Metabolic heterogeneity 3 demonstrated high predictive value for mediastinal occult lymph node metastasis (AUC=0.720, P=0.004).
CONCLUSION: Metabolism and heterogeneity, as measured by preoperative 18F-FDG PET/CT in lung invasive adenocarcinoma, potentially have clinical value for predicting mediastinal occult lymph node metastasis.
A critical event in the pathogenesis of kidney fibrosis is the transition of macrophages into myofibroblasts (MMT). Exosomes play an important role in crosstalk among cells in the kidney and the development of renal fibrosis. However, the role of myofibroblast-derived exosomes in the process of MMT and renal fibrosis progression remains unknown. Here, we examined the role of myofibroblast-derived exosomes in MMT and kidney fibrogenesis. In vitro, transforming growth factor-β1 stimulated the differentiation of kidney fibroblasts into myofibroblasts and promoted exosome release from myofibroblasts. RAW264.7 cells were treated with exosomes derived from myofibroblasts. We found purified exosomes from myofibroblasts trigger the MMT. By contrast, inhibition of exosome production with GW4869 or exosome depletion from the conditioned media abolished the ability of myofibroblasts to induce MMT. Mice treatment with myofibroblast-derived exosomes (Myo-Exo) exhibited severe fibrotic lesion and more abundant MMT cells in kidneys with folic acid (FA) injury, which was negated by TANK-banding kinase-1 inhibitor. Furthermore, suppression of exosome production reduced collagen deposition, extracellular matrix protein accumulation, and MMT in FA nephropathy. Collectively, Myo-Exo enhances the MMT and kidney fibrosis. Blockade of exosomes mediated myofibroblasts-macrophages communication may provide a novel therapeutic target for kidney fibrosis.
PURPOSE:To obtain a membrane having a hydrophilic polymer firmly retained thereon by retaining the polymer consisting mainly of hydroxyethyl(meth) acrylate, etc., on the porous surface of a porous polyolefin membrane. CONSTITUTION:A solution is prepared by dissolving the polymer consisting mainly of hydroxyethyl(meth)acrylate and hydroxypropyl(meth)acrylate in an org. solvent such as methanol and acetone or aq. solvent. Hydrophilic, bridgeable monomers capable of copolymerization or polymerization initiator may be added thereto. A porous polyolefin membrane is immersed in this solution to retain these monomers on at least a part of its porous surface. It is then polymerized by thermal polymerization or photopolymerization method. Finally, unreactive monomers or liberated polymers are removed with an org. solvent, etc. This method provides the membrane having a mechanical strength and the hydrophilic polymers firmly retained thereon.
Metformin has been the go‑to medical treatment for addressing type 2 diabetes mellitus (T2DM) as a frontline oral antidiabetic. Obesity, cancer and bone deterioration are linked to T2DM, which is considered a metabolic illness. Numerous diseases associated with T2DM, such as tumours, cardiovascular disease and bone deterioration, may be treated with metformin. Intervertebral disc degeneration (IVDD) is distinguished by degeneration of the spinal disc, accompanied by the gradual depletion of proteoglycans and water in the nucleus pulposus (NP) of the IVD, resulting in lower back pain. The therapeutic effect of metformin on IVDD has also attracted much attention. By stimulating AMP‑activated kinase, metformin could enhance autophagy and suppress cell senescence, apoptosis and inflammation, thus effectively delaying IVDD. The present review aimed to systematically explain the development of IVDD and mechanism of metformin in the treatment and prevention of IVDD to provide a reference for the clinical application of metformin as adjuvant therapy in the treatment of IVDD.
BACKGROUND: Under the general trend of global aging, geriatric comorbidity is increasingly common, which may have some impact on the quality of life of the older people. Self-management can effectively improve patient compliance, subjective initiative, and improve patient quality of life. However, the present situation of self-management in different old people is different. Therefore, this study classifies older co-morbid patients through potential profiling analysis, understands the category characteristics of self-management level of older co-morbid patients, and discusses the influencing factors of self-management level of different categories of older co-morbid patients, which can provide reference for personalized intervention programs for different comorbidity characteristics of elderly people in the future.  METHOD: Through a cross-sectional study, 616 cases of older co-morbid patients in three districts of Zhengzhou City, Henan Province, were selected as survey subjects by using the whole cluster sampling method. The General Information Questionnaire, Chronic Disease Self-Management Scale, Health Literacy Scale, Electronic Health Literacy Scale, Collaborative Social Support Scale, and Health Empowerment Scale were used to conduct the survey.
RESULTS: The result of LPA shows that the self-management characteristics of older co-morbid patients should be classified into 3 categories: good self-management (19.4%), medium self-management(27.9%), and low self-management (52.7%). The results of multivariate logistic regression analyses show that literacy, religiosity, health literacy, e-health literacy, appreciative social support, and health empowerment are influential factors for self-management among older co-morbid patients (p < 0.05).
CONCLUSION: There is obvious heterogeneity in the self-management level of older co-morbid patients. It is recommended that healthcare professionals give targeted interventions for their weaknesses according to the self-management characteristics of different categories of patients in order to enhance the self-management level of this population and improve their quality of life.
PURPOSE: To obtain the infection-preventing function-increasing agent containing royal jelly as a raw material, having a function for preventing the infection of bacteria, etc., capable of being easily added to foods, beverages, etc., and capable of being readily orally ingested. CONSTITUTION: The aqueous suspension of raw royal jelly or a crude protein solution obtained by salting out the raw royal jelly, etc., is treated preferably with two or more proteases different in the action sites, respectively, on a substrate to obtain a transparent solution containing peptides having mol.wts. of <=3000. The solution is, if necessary, further ground to obtain the infection- preventing function-increasing agent. The infection-preventing function-increasing agent may be ingested as such, after mixed with, e.g. honey, or after mixed with a nutritive drink, a refreshing drinking water, etc.
PURPOSE:To obtain a lipophilic liquid bile acid composition having high uniformity and fluidity, quickly and uniformly dispersible even in an oily substance and stable over a long period, by using bile acid and a glycerol fatty acid ester as essential components. CONSTITUTION:The objective composition can be produced by mixing and agitating (A) 70pts.wt. of a bile acid (e.g. cholic acid or ursodeoxycholic acid) and (B) 100pts.wt. of a glycerol fatty acid ester (e.g. tetraglycerol polyricinoleate or hexaglycerol pentaoleate) with a stirring mixer or a homomixer at room temperature - 80 deg.C. As necessary, the composition is incorporated with preservative, thickener, excipient, flavor, sweetener, colorant, etc. Bile acid is a medicine having appetizing effect for animal and absorbefacient action to oily substance and, accordingly, oily substance is added to an animal or fish feed to promote the growth of the animal, etc. Since bile acid is powder scarcely soluble in water and oily substance, it is uniformly dispersed in an oily substance by adding a glycerol fatty acid.
Avoid the oral route when the clinical disorder would prevent proper absorption. Bile salts must be given with the tablets when the endogenous supply of bile to the gastrointestinal tract is deficient. The coagulant effects of phytonadione tablets are not immediate; improvement of international normalized ratio (INR) may take 1 to 8 hours. Interim use of whole blood or component therapy may also be necessary if bleeding is severe.

Phytonadione tablets will not counteract the anticoagulant action of heparin.

When phytonadione tablets are used to correct excessive anticoagulant-induced hypoprothrombinemia, anticoagulant therapy still being indicated, the patient is again faced with the clotting hazards existing prior to starting the anticoagulant therapy. Phytonadione is not a clotting agent, but overzealous therapy with vitamin K1 may restore conditions which originally permitted thromboembolic phenomena. Dosage should be kept as low as possible, and prothrombin time should be checked regularly as clinical conditions indicate.
Novel mannanases comprising e.g. an amino acid sequence as shown in positions 31-330 of SEQ ID NO: 2 or their homologues may be derived from e.g. Bacillus sp. 1633, or may be encoded by polynucleotide molecules comprising a nucleotide sequence as shown in SEQ ID NO: 1 from nucleotide 91 to nucleotide 990, polynucleotide molecules that encode a polypeptide that is at least 65 % identical to the amino acid sequence of SEQ ID NO: 2 from amino acid residue 31 to amino acid residue 330, or degenerate nucleotide sequences thereof. The mannanases are alkaline and are useful e.g. in cleaning compositions, in a fracturing fluid useful to fracture a subterranean formation, for modifying plant material, and for treatment of cellulosic fibres.
The Cardiovalve offers a mitral replacement valve delivered through a transfemoral access and transseptal approach, and is intended to reduce mortality and adverse event rates in selected patients for whom surgical options are not feasible.

Innovation: A truly trans femoral, trans venous delivery of the prosthetic mitral valve which minimizes procedural risk. The Cardiovalve Implant features a dual nitinol frame for robust radial strength with decoupling of the atrial flange and ventricular portion which contains 24 grasping legs designed for atraumatic anchoring of the device to the native mitral annulus. Valve leaflets are made of bovine pericardium. The Cardiovalve implant has a very low left ventricle (LV) protrusion footprint thus reducing the risk of LV outflow tract obstruction and/or interference with the LV. The Cardiovalve delivery system (DS) is designed for transfemoral delivery of the Implant with transseptal access to the left atrium. The catheter assembly is used to center the implant relative to the native mitral valve plane and align it with the left ventricual apex-to-base axis. After valve implantation, the delivery system is withdrawn.
This study initiated by The first affiliated hospital of zhejiang university. Professor Shao-hua Hu will be PI of the study. There are about 80 patients with bipolar II depressive episode were involved in this study, all participants after 4 weeks of monotherapy (quetiapine or lurasidone). Group A: Those patients who were treated effectively over the 4th weekend {Reduction rate of 17 items of the Hamilton Depression Scale (HDS-17) \>50%} continued with the original regimen for 4 weeks. Subjects who did not meet valid criteria (HSDRS-17 subscore ratio\<50%) were randomly assigned to two treatment groups: group B (quetiapine/lurasidone + vortioxetine tablets) and group C (quetiapine/lurasidone + sodium valproate sustained release tablets). Subjects in group B were given vortioxetine in combination with their original treatment regimen at week 5; Subjects in group C began to receive sodium valproate sustained-release tablets in combination with the original treatment regimen at week 5. All three groups were observed at the end of the 16th week.

Group A: single drug treatment group: quetiapine tablet 300mg\~600mg/d or Lurasidone tablet 40-120mg /d; Group B: quetiapine tablets 300mg\~600mg/d or Lurasidone tablets 40-120mg /d+ vortioxetine 5-10mg /d Group C: quetiapine tablets 300mg\~600mg/d or Lurasidone tablets 40-120mg /d+ sodium valproate sustained release tablets 0.5-1.0 /d Quetiapine or lurasidone is currently the first-line treatment for bipolar II depressive episodes, ensuring effective treatment for all subjects. The study program will last 16 weeks with seven study visits including screening. For the consideration of scientific, legal and ethical factors, 100 subjects are initially planned to be enrolled in this experiment.
AIMS: Although electrical activity of the normal human heart is well characterized by the electrocardiogram, detailed insights into within-subject and between-subject variations of ventricular activation and recovery by noninvasive electroanatomic mapping are lacking. We characterized human epicardial activation and recovery within and between normal subjects using non-invasive electrocardiographic imaging (ECGI) as a basis to better understand pathology.
METHODS AND RESULTS: Epicardial activation and recovery were assessed by ECGI in 22 normal subjects, 4 subjects with bundle branch block (BBB) and 4 with long-QT syndrome (LQTS). We compared characteristics between the ventricles [left ventricle (LV) and right ventricle (RV)], sexes, and age groups (<50/≥50years). Pearson's correlation coefficient (CC) was used for within-subject and between-subject comparisons. Age of normal subjects averaged 49 ± 14 years, 6/22 were male, and no structural/electrical heart disease was present. The average activation time was longer in LV than in RV, but not different by sex or age. Electrical recovery was similar for the ventricles, but started earlier and was on average shorter in males. Median CCs of between-subject comparisons of the ECG signals, activation, and recovery patterns were 0.61, 0.32, and 0.19, respectively. Within-subject beat-to-beat comparisons yielded higher CCs (0.98, 0.89, and 0.82, respectively). Activation and/or recovery patterns of patients with BBB or LQTS contrasted significantly with those found in the normal population.
CONCLUSION: Activation and recovery patterns vary profoundly between normal subjects, but are stable individually beat to beat, with a male preponderance to shorter recovery. Individual characterization by ECGI at baseline serves as reference to better understand the emergence, progression, and treatment of electrical heart disease.
PURPOSE: To prepare a new style plaster (external plaster) or poultice (external liniment) expressing a synergistic effect by adding a hydroelectromagnetic phenomenon effect effective for muscular stiffness such as shoulder stiffness, muscular fatigue, etc., to the medicinal effect ingredients of the plaster (external plaster) or the poultice (external liniment) aiming the therapy or syndrome improvement of the muscular stiffness such as shoulder stiffness, and muscular pains such as muscular fatigue and lumbago. CONSTITUTION: Fine particles of a permanent magnet are homogeneously mixed with the medicinal effect ingredient base agents of a plaster (external plaster) or a poultice (external liniment). A synthetic resin raw material or synthetic rubber raw material is homogeneously mixed with the fine particles of the permanent magnet, and processed into a flexible magnetic sheet. The flexible magnetic sheet is used together with a conventional plaster (external plaster). The magnetic sheet is preferably subjected to an adhesive processing treatment enabling to adhere to skins so that the magnetic sheet can singly be used for a magnetic therapy. Thereby, the magnetic plaster can widely be applied as a magnetic force-generating source instead of the conventional Elekiban style source.
This study is a phase I, single arm, open-label trial of PD0332991 in combination with paclitaxel in patients with Rb-expressing metastatic breast cancer. Patients will be treated as shown in the schema below. Up to 20 patients are anticipated to be enrolled to reach the MTD of PD0332991 in combination with Paclitaxel. Once the MTD is established, an additional expanded cohort of 10 patients will be enrolled at that dose to establish the RP2D, obtain additional safety data and perform exploratory biomarker studies. The primary endpoint will be assessed after one cycle of therapy. Patients will remain on study until dose limiting toxicity, disease progression or physician/patient discretion. Safety assessment will continue for the duration of patient participation.